

# EBMT Bylaw Amendments

Positioning EBMT for governance maturity, risk resilience and scientific alignment

February 2026



# *Presentation summary*

1. Overview of bylaw amendments
2. Governance and oversight
3. Risk and compliance
4. Scientific alignment
5. Summary and outcomes



# Map of the Bylaw Amendments

## §2 Board

- Strategy and policies
- Risk oversight
- Membership fee approval

## §6 President

- Delegations for risk and compliance
- Managing Director and Chief Medical Officer oversight

## §11 Scientific Council

- Policy drafting
- Board portfolios
- Project Management Office participation

## §15 Annual Meeting

- Allows virtual and hybrid meeting modes

## §3 Assembly

- Adds policy approval for science and education

## §8 Treasurer

- Financial controls
- Audits and financial risk

## §13 Committees

- Scientific and operational committee's framework
- Reporting

## §4, §14 Membership

- Clarifies categories
- DCF core wording
- Non-payment rules

## §5 Executive Committee

- Composition updated
- Risk and compliance
- Execution steering

## §9 Project Management Office

- New and expanded science portfolio governance
- Risk escalation

## Working Parties

- Term limits
- Structure endorsement
- Annual reporting

## §16 General Assembly

- Extraordinary General Assembly convening provisions

The following slides highlights each amended area in blue and the governance intent behind it.

# Strengthening governance and oversight

- **Science first:** the proposed changes place science at the core of EBMT governance and decision-making
- **Decision rights:** GA, Board and ExCom roles and escalation are explicit
- **Oversight:** policies have owners, review cadence and reporting
- **Portfolio governance:** committees run on a consistent model across workstreams



# Governance overview

Clear decision rights + structured scientific and risk oversight

- Key outcome: governance becomes explicit, consistent, and scalable — without changing the member-led nature of EBMT.
- GA retains voting authority (elections + key approvals).
- Board strengthens strategic and policy oversight (incl. risk appetite).
- ExCom steers execution and supervises risk/compliance, informed by PMO proposals.



# §2 Board

– stronger oversight and clearer remit

Strategy, policy governance, and enterprise risk oversight

## What is added / clarified

- Explicit oversight of scientific & educational policies
- Approval and oversight of EBMT policies
- Oversight/advice on financial and non-financial risks
- Defines risk appetite and compliance expectations

## Composition + engagement

- Can invite stakeholders (voice, no vote)
- Majority voting; President tie-break
- Membership fee discussed/approved by Board



# §5 Executive Committee (ExCom)

– execution steering with science + risk embedded

Composition updated; risk/compliance supervision formalized

## Composition

- Adds Scientific Council Chair and Co-chair
- Connects Board ↔ EBMT Offices
- Ex officio Board of the EBMT Foundation

## Core accountabilities

- Supervises scientific/educational policies and EBMT policies
- Oversees risk management (financial + non-financial)
- Supervises compliance program implementation
- Takes final decisions within remit based on PMO proposals



# §5 Project Management Office (PMO)

– portfolio governance for science

Single structured interface for studies, grants, data requests and external partners

## What the PMO does (new/expanded bylaw section)

- Organises and monitors studies, grants, and science-related activities aligned to strategy
- Consolidates proposals and prepares decision options for ExCom (portfolio prioritisation)
- Monitors performance, timelines, resources, KPIs; reports to ExCom
- Identifies and escalates scientific project risks with mitigation proposals

## PMO membership

- Chief Medical Officer (leads)
- Managing Director
- Scientific Council Chair + Co-chair
- Other members per organisational regulations



# Stronger risk and compliance management

- **Oversight:** financial and non-financial risks covered
- **Risk appetite:** defined thresholds and ownership
- **Escalation:** PMO route and decision points



# Overview of the roles and responsibilities Part 1

## §6 President

- Supervises MD + CMO; ensures strategy and policies implemented
- Delegates non-financial risk and compliance execution via MD
- Delegates financial risk implementation to Treasurer

## §8 Treasurer

- Strengthens internal financial management and accountability
- Reviews audits; recommends corrective measures
- Implements financial risk strategy and transparency

## §7 Secretary

- Coordinates Board + GA (with offices/President)
- Monitors Board/ExCom ensuring bylaws maintained and updated
- Maintains membership information and communication

## Managing Director (MD)

- Executes strategy; oversees operations of EBMT units
- Permanent PMO member; science-related responsibilities via PMO
- Drives organisational performance and stakeholder engagement

## Chief Medical Officer (CMO)

- Leads PMO; coordinates science-related activities and proposals
- Supports clinical standards and scientific partnerships
- Supervises publication list and WP indicators (per bylaws)

- The following slides summarise Who owns what: oversight, delegation, and execution. Accountability by design.
- Net effect: clearer accountability, faster decisions, and stronger controls for both scientific and operational activities.

# Overview of the roles and responsibilities Part 2

## Working Parties

- Board can establish/dismantle WPs after consulting SC (GA approval)
- Term limits: Chair 1×4y; Secretary 1×4y; Subcommittee leaders 1×4y
- Max 12 years across WP Chair (4y) + ExCom member (8y)
- Annual reporting on activities, publications, and resources
- WP governance structure endorsed by Board

## §4, §14 Membership

- Full membership requires annual submission of “DCF core” data
- Associate membership: no voting rights; now eligible for accreditation

## §13 Committees

- Board may create/dissolve committees; committees accountable to Board
- Scientific committees formed after consultation with SC
- Adds non-scientific/operational committees (strategic, financial, transformation)
- Chairs may attend Board when relevant (voice, no vote)
- Term limits: Chair/Secretary/Subcommittee leader 1×4y

## §3, §16 General Assembly

- Extraordinary GA may be convened by President (if needed / ExCom request)

- Governance controls reinforced -Consistency, continuity, and accountable use of EBMT resources
- Operational modernization - Clearer membership rules and formal policy approval link
- Structured reporting → better visibility of outcomes, resources, and risk
- Term limits → renewal, continuity planning, and reduced key-person dependency
- Board endorsement of structures → consistent governance across EBMT scientific bodies
- Board/ExCom can invite committee chairs and stakeholders to improve alignment (voice, no vote).

# Science-led decision making and alignment

- Scientific Council drafts scientific and educational policy for GA approval
- Scientific Council leadership embedded in ExCom and PMO
- Working Parties and committees aligned through consistent reporting and oversight



# §11 Scientific Council

science-led governance, structurally

Policy drafting + Board portfolios + PMO participation

## Mandate

- Drafts scientific and educational policy for GA approval
- Evaluates Working Party activities and reports to Board
- Advises Board on scientific and educational issues

## Representation & integration

- SC Chair/Co-chair participate in PMO
- SC reps participate in key EBMT committees (Education/Registry)



# *Summary of changes. What a “YES” vote delivers*

1. **Governance:** clearer decision rights and policy oversight
2. **Risk:** explicit oversight for financial and non-financial risk, with defined risk appetite
3. **Science:** Scientific Council and Project Management Office integrated into executive decisions
4. **Delivery:** Project Management Office enables structured portfolio management and risk escalation
5. **Transparency:** reporting and term limits strengthen continuity and accountability



**Outcome:**  
better governance,  
stronger risk controls,  
and science-led decisions.

These amendments have **already been approved** by the **Executive Committee** and the **Board of Association**.



# Thank You

[ebmt.org](https://ebmt.org) |       

